


CLAIM AMENDMENTS

1. **(Currently Amended)** A method of inhibiting histone deacetylation activity in cells comprising contacting the cells with an effective amount of a compound wherein the compound is 5-phenyl-2,4-pentadienoic acid, 7-phenyl-2,4,6-heptatrienoic acid, 7-phenyl-2,4,6-hepta-
trienoylhydroxamic acid, 8-phenyl-3,5,7-octatrienoic acid, cinnamoylhydroxamic acid, methyl-
cinnamoylhydroxamic acid, 5-phenyl-2,4-pentadienoylhydroxamic acid, N-methyl-5-phenyl-2,4-
pentadienoylhydroxamic acid, 3-methyl-5-phenyl-2,4-pentadienoylhydroxamic acid, 4-methyl-5-
phenyl-2,4-pentadienoyl hydroxamic acid, 4-chloro-5-phenyl-2,4-pentadienoylhydroxamic acid,
5-phenyl-2-en-4-yn-pentanoylhydroxamic acid, or N-methyl-6-phenyl-3,5-
hexadienoylhydroxamic acid of formula (I), thereby treating one or more disorders mediated by
histone deacetylase; said compound having the following formula:



wherein

~~A is a cyclic moiety selected from the group consisting of aryl, or heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy;~~
~~each of Y¹ and Y², independently, is a bond;~~

~~L is a straight C₂-12 hydrocarbon chain containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; said hydrocarbon chain being optionally substituted with C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, hydroxyl, halo, amino, nitro, cyano, C₃₋₅ cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkyloxycarbonyl, C₁₋₄ alkylcarbonyl, or formyl; and further being optionally interrupted by O, N(R^e), N(R^e)C(O)O, -O-C(O)N(R^e), N(R^e)C(O)-N(R^f), or O-C(O)O; each of R^e and R^f, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;~~

~~X¹ is O or S; and~~

~~X² is OR¹, SR¹, NR³-OR¹, NR³-SR¹, C(O)-OR¹, -CHR⁴-OR¹, N=N-C(O)-N(R³)₂,~~
~~or -O-CHR⁴-O-C(O)-R⁵, where each of R¹ and R², independently, is hydrogen, alkyl,~~
~~hydroxylalkyl, haloalkyl, or a hydroxyl protecting group; R³ is hydrogen, alkyl, alkenyl, alkynyl,~~
~~alkoxy, hydroxylalkyl, hydroxyl, haloalkyl, or an amino protecting group; R⁴ is hydrogen, alkyl,~~
~~hydroxylalkyl, or haloalkyl; and R⁵ is alkyl, hydroxylalkyl, or haloalkyl;~~
~~or a salt thereof; and~~

determining whether the level of acetylated histones in the treated cells is higher than in untreated cells under the same conditions.

Claims 2-40. (**Cancelled**)

41. (**Currently Amended**) The method of claim 1, wherein said compound is 5-phenyl-2,4-pentadienoic acid, 8-phenyl-3,5,7-octatrienoic acid, 5-phenyl-2,4-pentadienoylhydroxamic acid, or 7-phenyl-2,4,6-hepta-trienoylhydroxamic acid.

Claims 42-43. (**Cancelled**)

44. (**Original**) The method of claim 1, wherein the cells being treated are cancerous.

45. (**Cancelled**)

46. (**Previously Presented**) The method of claim 1, wherein the disorder is cancer.

Claims 47-66 (**Cancelled**)

67. (**Currently Amended**) The method of claim [[40]] 1, wherein said compound is 5-phenyl-2,4-pentadienoic acid.

Claims 68-73 (**Cancelled**)

74. (**Currently Amended**) The method of claim [[40]] 1, wherein said compound is 7-phenyl-2,4,6-heptatrienoic acid.

75. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 8-phenyl-3,5,7-octatrienoic acid.

76. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is cinnamoylhydroxamic acid.

77. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is methyl-cinnamoylhydroxamic acid.

78. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 5-phenyl-2,4-pentadienoylhydroxamic acid.

79. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is N-methyl-5-phenyl-2,4-pentadienoylhydroxamic acid.

80. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 3-methyl-5-phenyl-2,4-pentadienoylhydroxamic acid.

81. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 4-methyl-5-phenyl-2,4-pentadienoyl hydroxamic acid.

82. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 4-chloro-5-phenyl-2,4-pentadienoylhydroxamic acid.

83. **(Cancelled)**

84. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is 5-phenyl-2-en-4-yn-pentanoylhydroxamic acid.

85. **(Currently Amended)** The method of claim [[40]] 1, wherein said compound is N-methyl-6-phenyl-3,5-hexadienoylhydroxamic acid.